Literature DB >> 19404606

[Affective disorders. The significance of psychotherapeutic approaches].

M Berger1, E L Brakemeier, C Klesse, E Schramm.   

Abstract

The use of psychotherapeutic strategies is essential in the treatment of affective disorders. Psychotherapy proved to be at least equivalent to antidepressant medication in the treatment of mild to moderate depression. In severe cases, the combination of both treatments is considered by guidelines to be the standard treatment. Psychotherapeutic approaches show a longer latency than antidepressants; however, the effects are longer lasting. Regarding the effectiveness of pharmacotherapy sobering results have been published recently. Therefore, the further development of psychotherapy deserves special attention. Cognitive behavioral therapy and interpersonal therapy provide the highest evidence. The empirical basis for psychodynamic psychotherapies is still limited. In the treatment of chronic depression a new approach--cognitive behavioral analysis system of psychotherapy--is gaining importance. There is a trend towards an increasing specification of psychotherapy for distinct subgroups of depressed patients. Challenges for the future include increasing treatment efficacy, investigating mechanisms of efficacy and predictors for a differential indication, and making effective approaches generally available to all patients.

Entities:  

Mesh:

Year:  2009        PMID: 19404606     DOI: 10.1007/s00115-008-2624-x

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  52 in total

1.  Comparing the effectiveness of process-experiential with cognitive-behavioral psychotherapy in the treatment of depression.

Authors:  Jeanne C Watson; Laurel B Gordon; Lana Stermac; Freda Kalogerakos; Patricia Steckley
Journal:  J Consult Clin Psychol       Date:  2003-08

2.  A meta-analysis of the effects of cognitive therapy in depressed patients.

Authors:  V Gloaguen; J Cottraux; M Cucherat; I M Blackburn
Journal:  J Affect Disord       Date:  1998-04       Impact factor: 4.839

3.  Reducing relapse and recurrence in unipolar depression: a comparative meta-analysis of cognitive-behavioral therapy's effects.

Authors:  Jeffrey R Vittengl; Lee Anna Clark; Todd W Dunn; Robin B Jarrett
Journal:  J Consult Clin Psychol       Date:  2007-06

4.  Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database.

Authors:  A Khan; H A Warner; W A Brown
Journal:  Arch Gen Psychiatry       Date:  2000-04

5.  Comparative effects of short-term psychodynamic psychotherapy and cognitive-behavioral therapy in depression: a meta-analytic approach.

Authors:  F Leichsenring
Journal:  Clin Psychol Rev       Date:  2001-04

6.  Randomized trial of weekly, twice-monthly, and monthly interpersonal psychotherapy as maintenance treatment for women with recurrent depression.

Authors:  Ellen Frank; David J Kupfer; Daniel J Buysse; Holly A Swartz; Paul A Pilkonis; Patricia R Houck; Paola Rucci; Danielle M Novick; Victoria J Grochocinski; Deborah M Stapf
Journal:  Am J Psychiatry       Date:  2007-05       Impact factor: 18.112

7.  Efficacy of interpersonal psychotherapy as a maintenance treatment of recurrent depression. Contributing factors.

Authors:  E Frank; D J Kupfer; E F Wagner; A B McEachran; C Cornes
Journal:  Arch Gen Psychiatry       Date:  1991-12

8.  Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse.

Authors:  L L Judd; H S Akiskal; J D Maser; P J Zeller; J Endicott; W Coryell; M P Paulus; J L Kunovac; A C Leon; T I Mueller; J A Rice; M B Keller
Journal:  J Affect Disord       Date:  1998-09       Impact factor: 4.839

Review 9.  Combined pharmacotherapy and psychological treatment for depression: a systematic review.

Authors:  Sandro Pampallona; Paola Bollini; Giuseppe Tibaldi; Bruce Kupelnick; Carmine Munizza
Journal:  Arch Gen Psychiatry       Date:  2004-07

10.  Psychotherapy alone and combined with pharmacotherapy in the treatment of depression.

Authors:  Frans de Jonghe; Mariëlle Hendricksen; Gerda van Aalst; Simone Kool; Vjaap Peen; Rien Van; Ellen van den Eijnden; Jack Dekker
Journal:  Br J Psychiatry       Date:  2004-07       Impact factor: 9.319

View more
  4 in total

1.  General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry.

Authors:  Thomas C Baghai; Pierre Blier; David S Baldwin; Michael Bauer; Guy M Goodwin; Kostas N Fountoulakis; Siegfried Kasper; Brian E Leonard; Ulrik F Malt; Dan Stein; Marcio Versiani; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-11       Impact factor: 5.270

2.  Executive summary of the report by the WPA section on pharmacopsychiatry on general and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders.

Authors:  Thomas C Baghai; Pierre Blier; David S Baldwin; Michael Bauer; Guy M Goodwin; Kostas N Fountoulakis; Siegfried Kasper; Brian E Leonard; Ulrik F Malt; Dan J Stein; Marcio Versiani; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-11-15       Impact factor: 5.270

3.  [Evidence-based therapy of depression: S3 guidelines on unipolar depression].

Authors:  M Härter; C Klesse; I Bermejo; T Bschor; J Gensichen; T Harfst; M Hautzinger; C Kolada; I Kopp; C Kühner; M Lelgemann; J Matzat; B Meyerrose; C Mundt; W Niebling; G Ollenschläger; R Richter; H Schauenburg; H Schulz; S Weinbrenner; F Schneider; M Berger
Journal:  Nervenarzt       Date:  2010-09       Impact factor: 1.214

Review 4.  The treatment of chronic depression with cognitive behavioral analysis system of psychotherapy: a systematic review and meta-analysis of randomized-controlled clinical trials.

Authors:  Philip Negt; Eva-Lotta Brakemeier; Johannes Michalak; Lotta Winter; Stefan Bleich; Kai G Kahl
Journal:  Brain Behav       Date:  2016-05-03       Impact factor: 2.708

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.